Pacific Biosciences Of California, INC. 8-K Filing

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share PACB The NASDAQ Stock Market

Filing Documents

• pacb-20251105.htm (8-K) — 23KB
• pacb-ex991xearningsrelease.htm (EX-99.1) — 253KB
• 0001299130-25-000165.txt ( ) — 407KB
• pacb-20251105.xsd (EX-101.SCH) — 2KB
• pacb-20251105_lab.xml (EX-101.LAB) — 21KB
• pacb-20251105_pre.xml (EX-101.PRE) — 12KB
• pacb-20251105_htm.xml (XML) — 3KB

02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On November 5, 2025, Pacific Biosciences of California, Inc. (the "Company") announced its financial results for its third fiscal quarter ended September 30, 2025. A copy of the press release containing the announcement is attached as Exhibit 99.1 hereto and is incorporated herein by reference. The information furnished in this Item 2.02 and Exhibit 99.1 attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01. FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. 99.1 Press Release dated November 5 , 2025, titled "PacBio Announces Third Quarter 2025 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pacific Biosciences of California, Inc. By: /s/ Michele Farmer Michele Farmer Vice President and Chief Accounting Officer Date: November 5, 2025

View Full Filing

View this 8-K filing on SEC EDGAR